| Title | Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study |
| Authors | Shi, Yuankai He, Xiaohui Yang, Sheng Ai, Bin Zhang, Changgong Huang, Dingzhi Dong, Mei Liu, Peng Zhou, Shengyu Han, Xiaohong |
| Affiliation | Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100021, Peoples R China. Peking Univ, Coll Med, Beijing 100871, Peoples R China. |
| Keywords | ramosetron ondansetron 5-hydroxytryptamine receptor 3 antagonist emesis CISPLATIN-BASED CHEMOTHERAPY 5-HT3 RECEPTOR ANTAGONISTS EMESIS GRANISETRON SCHEDULES CANCER |
| Issue Date | 2007 |
| Publisher | chemotherapy |
| Citation | CHEMOTHERAPY.2007,53,(1),44-50. |
| Abstract | Background: This study observed and compared the preventive effects of ramosetron and ondansetron on gastrointestinal side effects caused by cisplatin-containing chemotherapy. Methods: Fifty patients with malignant tumors undergoing their first chemotherapy were randomly divided into two groups, and each group received 0.3 mg of ramosetron and 16 mg of ondansetron in a prospective crossover comparison study. Results: Data were collected for analysis of the therapeutic effect in 47 cases and for adverse events in 50 cases. Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss. From days 3 - 5, ramosetron tended to be more effective than ondansetron in its antiemetic action. The incidence of headache, fatigue and constipation was the same for both drugs. Conclusions: Ramosetron is a long-lasting and safe antiemetic agent. Copyright (c) 2007 S. Karger AG, Basel |
| URI | http://hdl.handle.net/20.500.11897/398006 |
| ISSN | 0009-3157 |
| DOI | 10.1159/000098418 |
| Indexed | SCI(E) |
| Appears in Collections: | 待认领 |
